MA33274B1 - Dérivés de la thiéno [2, 3-b] pyridine servant d'inhibiteurs de réplication virale - Google Patents

Dérivés de la thiéno [2, 3-b] pyridine servant d'inhibiteurs de réplication virale

Info

Publication number
MA33274B1
MA33274B1 MA34351A MA34351A MA33274B1 MA 33274 B1 MA33274 B1 MA 33274B1 MA 34351 A MA34351 A MA 34351A MA 34351 A MA34351 A MA 34351A MA 33274 B1 MA33274 B1 MA 33274B1
Authority
MA
Morocco
Prior art keywords
compounds
relates
viral infections
antiviral activity
thieno
Prior art date
Application number
MA34351A
Other languages
Arabic (ar)
English (en)
Inventor
Dorothée Bardiot
Patrick Chaltin
Frauke Christ
Zeger Debyser
Maeyer Marc De
Arnaud Marchand
Damien Marchand
Arnout Voet
Original Assignee
Univ Leuven Kath
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40834066&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33274(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Leuven Kath filed Critical Univ Leuven Kath
Publication of MA33274B1 publication Critical patent/MA33274B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention a pour objet une série de composés de formule (A) ayant une activité antivirale, plus spécifiquement des propriétés inhibitrices sur la réplication du VIH (Virus d'Immunodéficience Humaine). L'invention concerne également des procédés pour la préparation de ces composés, ainsi que de nouveaux intermédiaires utiles dans une ou plusieurs étapes de ces synthèses. L'invention concerne également des compositions pharmaceutiques comprenant une quantité efficace de ces composés en tant qu'ingrédients actifs. Cette invention concerne en outre l'utilisation de ces composés en tant que médicaments ou dans la fabrication d'un médicament utile pour le traitement d'animaux souffrant d'infections virales, en particulier d'une infection au VIH. Cette invention concerne en outre des procédés pour le traitement d'infections virales chez des animaux par l'administration d'une quantité thérapeutique de ces composés, combinée facultativement à un ou plusieurs autres médicaments ayant une activité antivirale.
MA34351A 2009-05-15 2010-05-17 Dérivés de la thiéno [2, 3-b] pyridine servant d'inhibiteurs de réplication virale MA33274B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0908394.0A GB0908394D0 (en) 2009-05-15 2009-05-15 Novel viral replication inhibitors
US34380310P 2010-05-03 2010-05-03
PCT/EP2010/056754 WO2010130842A1 (fr) 2009-05-15 2010-05-17 Dérivés de la thiéno [2, 3-b] pyridine en tant qu'inhibiteurs de réplication virale

Publications (1)

Publication Number Publication Date
MA33274B1 true MA33274B1 (fr) 2012-05-02

Family

ID=40834066

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34351A MA33274B1 (fr) 2009-05-15 2010-05-17 Dérivés de la thiéno [2, 3-b] pyridine servant d'inhibiteurs de réplication virale

Country Status (29)

Country Link
US (2) US8785638B2 (fr)
EP (1) EP2430029B1 (fr)
JP (2) JP2012526778A (fr)
KR (2) KR20120035162A (fr)
CN (2) CN105367583A (fr)
AP (1) AP2939A (fr)
BR (1) BRPI1010833A2 (fr)
CA (1) CA2759500A1 (fr)
CL (1) CL2011002878A1 (fr)
CO (1) CO6460769A2 (fr)
CR (1) CR20110601A (fr)
CU (1) CU24117B1 (fr)
DO (1) DOP2011000343A (fr)
EA (1) EA201171376A1 (fr)
EC (1) ECSP11011456A (fr)
GB (1) GB0908394D0 (fr)
GE (1) GEP20146115B (fr)
IL (1) IL216357A0 (fr)
MA (1) MA33274B1 (fr)
MX (1) MX2011012146A (fr)
MY (1) MY161085A (fr)
NI (1) NI201100194A (fr)
NZ (1) NZ596392A (fr)
PE (1) PE20120779A1 (fr)
SG (1) SG175255A1 (fr)
TN (1) TN2012000074A1 (fr)
UA (1) UA104021C2 (fr)
WO (1) WO2010130842A1 (fr)
ZA (1) ZA201107618B (fr)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0908394D0 (en) 2009-05-15 2009-06-24 Univ Leuven Kath Novel viral replication inhibitors
US8338441B2 (en) 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
GB0913636D0 (en) 2009-08-05 2009-09-16 Univ Leuven Kath Novel viral replication inhibitors
MX2012015097A (es) 2010-07-02 2013-05-28 Gilead Sciences Inc Derivados de acido naft-2-ilacetico para tratar sida.
EP2588455B1 (fr) 2010-07-02 2018-04-04 Gilead Sciences, Inc. Dérivés de l'acide 2-quinolinyl-acétique en tant que composés antiviraux hiv
EP2640729B1 (fr) * 2010-11-15 2016-12-21 VIIV Healthcare UK Limited Inhibiteurs de la réplication du vih
KR20140003438A (ko) * 2010-11-15 2014-01-09 카톨리에케 유니버시테이트 루벤 항바이러스성 축합 헤테로사이클릭 화합물
EP2508511A1 (fr) 2011-04-07 2012-10-10 Laboratoire Biodim Inhibiteurs de la réplication virale, leur procédé de préparation et leurs utilisations thérapeutiques
EP2511273B8 (fr) 2011-04-15 2019-06-26 Hivih Inhibiteurs de la réplication virale, leur procédé de préparation et leurs utilisations thérapeutiques
UA111841C2 (uk) 2011-04-21 2016-06-24 Гіліад Сайєнсіз, Інк. Сполуки бензотіазолу та їх фармацевтичне застосування
US8791108B2 (en) 2011-08-18 2014-07-29 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
WO2013062028A1 (fr) 2011-10-25 2013-05-02 塩野義製薬株式会社 Inhibiteur de la réplication du vih
WO2013073875A1 (fr) * 2011-11-15 2013-05-23 한국화학연구원 Dérivé antiviral inédit de pyrrolopyridine et son procédé de production
US9376392B2 (en) 2012-01-04 2016-06-28 Gilead Sciences, Inc. 2-(tert-butoxy)-2-(7-methylquinolin-6-yl) acetic acid derivatives for treating AIDS
US9284323B2 (en) 2012-01-04 2016-03-15 Gilead Sciences, Inc. Naphthalene acetic acid derivatives against HIV infection
US9006235B2 (en) 2012-03-06 2015-04-14 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
KR101390616B1 (ko) 2012-03-28 2014-04-29 주식회사 두산 신규 화합물 및 이를 포함하는 유기 전계 발광 소자
UY34750A (es) * 2012-04-20 2013-11-29 Gilead Sciences Inc ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
CA2876370A1 (fr) * 2012-07-12 2014-01-16 Viiv Healthcare Uk Limited Composes et procedes de traitement du vih
US8906929B2 (en) 2012-08-16 2014-12-09 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
EP2716639A1 (fr) 2012-10-05 2014-04-09 Laboratoire Biodim Inhibiteurs de la réplication virale, leur procédé de préparation et leurs utilisations thérapeutiques
EP2716632A1 (fr) 2012-10-05 2014-04-09 Laboratoire Biodim Inhibiteurs de la réplication virale, leur procédé de préparation et leurs utilisations thérapeutiques
EP2719685A1 (fr) 2012-10-11 2014-04-16 Laboratoire Biodim Inhibiteurs de la réplication virale, leur procédé de préparation et leurs utilisations thérapeutiques
TW201441197A (zh) 2013-01-31 2014-11-01 Shionogi & Co Ｈｉｖ複製抑制劑
ES2619708T3 (es) 2013-03-13 2017-06-26 VIIV Healthcare UK (No.5) Limited Inhibidores de la replicación del virus de inmunodeficiencia humana
WO2014164467A1 (fr) 2013-03-13 2014-10-09 Bristol-Myers Squibb Company Inhibiteurs de la réplication du virus de l'immunodéficience humaine
WO2014164409A1 (fr) 2013-03-13 2014-10-09 Bristol-Myers Squibb Company Inhibiteurs de la réplication du virus de l'immunodéficience humaine
CN105008369B (zh) 2013-03-14 2017-07-11 百时美施贵宝公司 人类免疫缺陷病毒复制抑制剂
JP2016512558A (ja) 2013-03-14 2016-04-28 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ヒト免疫不全ウイルス複製の阻害剤
US9908893B2 (en) 2013-06-11 2018-03-06 Latvian Institute Of Organic Synthesis Thieno [2,3-b] pyridines as multidrug resistance modulators
EP2821104A1 (fr) 2013-07-05 2015-01-07 Laboratoire Biodim Inhibiteurs de la réplication virale, leur procédé de préparation et leurs utilisations thérapeutiques
EP2821082A1 (fr) 2013-07-05 2015-01-07 Laboratoire Biodim Procédé de production d'un lentivirus inactivé, notamment le VIH, vaccin, kit et procédé d'utilisation
ITRE20130056A1 (it) * 2013-07-29 2015-01-30 Roberto Quadrini Metodo e dispositivo per il bilanciamento di consumi elettrici
EP3105236B1 (fr) 2014-02-12 2017-10-18 ViiV Healthcare UK (No.5) Limited Utilisation de macrocycles de benzothiazole comme qu'inhibiteurs de la réplication du virus de l'immunodéficience humaine
US9834566B2 (en) 2014-02-18 2017-12-05 VIIV Healthcare UK (No.5) Limited Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication
US9409922B2 (en) 2014-02-18 2016-08-09 Bristol-Myers Squibb Company Imidazopyridine macrocycles as inhibitors of human immunodeficiency virus replication
WO2015126758A1 (fr) 2014-02-18 2015-08-27 Bristol-Myers Squibb Company Macrocycles d'imidazopyrimidine utilisés comme inhibiteurs de la réplication du virus de l'immunodéficience humaine
US9273067B2 (en) 2014-02-19 2016-03-01 Bristol-Myers Squibb Company Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication
PT3107913T (pt) 2014-02-19 2018-09-28 Viiv Healthcare Uk No 5 Ltd Inibidores da replicação do vírus da imunodeficiência humana
US9637501B2 (en) 2014-02-20 2017-05-02 Viiv Healthcare Uk (No. 5) Limited Pyridin-3-yl acetic acid macrocycles as inhibitors of human immunodeficiency virus replication
US9193720B2 (en) 2014-02-20 2015-11-24 Bristol-Myers Squibb Company Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
US9975906B2 (en) 2014-05-16 2018-05-22 Shionogi & Co., Ltd. Tricyclic heterocycle derivatives having HIV replication inhibitory effect
TR201807217T4 (tr) 2014-07-08 2018-06-21 Viiv Healthcare Uk Ltd Bir viral enfeksiyon sahasının tedavisinde kullanım için izoindolin türevleri.
TWI700284B (zh) 2015-05-29 2020-08-01 日商塩野義製藥股份有限公司 具有ｈｉｖ複製抑制作用之含氮３環性衍生物
US20180170903A1 (en) 2015-07-06 2018-06-21 VIIV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
RU2018102554A (ru) 2015-07-08 2019-08-08 ВАЙВ ХЕЛТКЕР ЮКей (N5) ЛИМИТЕД Производные пиридин-3-ил уксусной кислоты в качестве ингибиторов репликации вируса иммунодефицита человека
US20180170904A1 (en) 2015-07-09 2018-06-21 VIIV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
RU2018103031A (ru) 2015-07-09 2019-08-09 ВАЙВ ХЕЛТКЕР ЮКей (N5) ЛИМИТЕД Производные пиридин-3-ил уксусной кислоты в качестве ингибиторов репликации вируса иммунодефицита человека
KR20180035910A (ko) 2015-08-07 2018-04-06 비브 헬스케어 유케이 (넘버5) 리미티드 인간 면역결핍 바이러스 복제의 억제제로서 피리딘-3-일 아세트산 유도체
WO2017025913A1 (fr) 2015-08-10 2017-02-16 VIIV Healthcare UK (No.5) Limited Macrocycles d'imidazopyridine en tant qu'inhibiteurs de la réplication du virus de l'immunodéficience humaine
TWI657086B (zh) 2015-08-11 2019-04-21 英商Viiv醫療保健英國(No.5)有限公司 做為人類免疫缺陷病毒複製抑制劑之５－（ｎ－苯甲基四氫異喹啉－６－基）吡啶－３－基乙酸衍生物
US10214516B2 (en) 2015-08-12 2019-02-26 VIIV Healthcare UK (No.5) Limited 5-(N-fused tricyclic aryl tetrahydroisoquinolin-6-yl) pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
TW201718537A (zh) 2015-08-12 2017-06-01 Ｖｉｉｖ醫療保健英國（Ｎｏ．５）有限公司 做為人類免疫缺陷病毒複製抑制劑之吡啶－３－基乙酸衍生物
CN108137553A (zh) 2015-08-12 2018-06-08 Viiv保健英国第五有限公司 作为人免疫缺陷病毒复制的抑制剂的5-(n-[6,5]-稠合双环芳基四氢异喹啉-6-基)吡啶-3-基乙酸衍生物
KR20180038047A (ko) 2015-08-20 2018-04-13 비브 헬스케어 유케이 (넘버5) 리미티드 인간 면역결핍 바이러스 복제의 억제제로서 피리딘-3-일 아세트산 유도체
JP2018536001A (ja) 2015-12-04 2018-12-06 ヴィーブ ヘルスケア ユーケー リミテッド イソインドリン誘導体
US20190152957A1 (en) 2016-05-11 2019-05-23 VIIV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
JP2019515000A (ja) 2016-05-11 2019-06-06 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド ヒト免疫不全ウイルス複製の阻害剤としてのピリジン−３−イル酢酸誘導体
US10407410B2 (en) 2016-05-11 2019-09-10 VIIV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
EP3565810A1 (fr) 2017-01-03 2019-11-13 ViiV Healthcare UK (No.5) Limited Dérivés d'acide pyridin-3-yle acétique utilisés en tant qu'inhibiteurs de la réplication du virus de l'immunodéficience humaine
TW201835068A (zh) 2017-01-03 2018-10-01 英商Viiv醫療保健英國(No.5)有限公司 作為人類免疫缺乏病毒複製之抑制劑之吡啶-3-基乙酸衍生物
WO2019244066A2 (fr) 2018-06-19 2019-12-26 VIIV Healthcare UK (No.5) Limited Dérivés d'acide pyridin-3-yl-acétique en tant qu'inhibiteurs de la réplication du virus de l'immunodéficience humaine
WO2020003093A1 (fr) 2018-06-25 2020-01-02 VIIV Healthcare UK (No.5) Limited Dérivés d'acide pyridin-3-yl-acétique en tant qu'inhibiteurs de la réplication du virus de l'immunodéficience humaine
WO2020120528A1 (fr) * 2018-12-14 2020-06-18 F. Hoffmann-La Roche Ag Dérivés de chromen-4-one contenant n pour le traitement et la prophylaxie d'une infection par le virus de l'hépatite b
WO2022263557A1 (fr) * 2021-06-15 2022-12-22 Glaxosmithkline Intellectual Property Development Limited Composé pharmaceutique
CN113603655B (zh) * 2021-07-14 2022-12-16 上海应用技术大学 一种4-羟基-2-甲基-3-(苯磺酰基)噻唑烷-2-羧酸甲酯化合物的制备方法
CN113461632B (zh) * 2021-07-15 2022-12-16 上海应用技术大学 3-((4-氟苯基)磺酰基)-4-羟基-2-甲基噻唑烷-2-羧酸甲酯的制备方法
CN119699325B (zh) * 2024-12-17 2025-12-16 宁夏农林科学院植物保护研究所（宁夏植物病虫害防治重点实验室） 一种西花蓟马引诱组合物及应用

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1121922A (en) 1966-06-17 1968-07-31 Ici Ltd Pyrimidine derivatives
US4698340A (en) 1984-07-19 1987-10-06 Fujisawa Pharmaceutical Co., Ltd. Pyrimidine derivatives, processes for preparation thereof and composition containing the same
DE3609596A1 (de) 1986-03-21 1987-10-01 Hoechst Ag 2-azolylmethyl-2-aryl-1,3-dioxolane und deren salze, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung
AU651986B2 (en) 1991-04-22 1994-08-11 Otsuka Pharmaceutical Factory, Inc. Pyrazolo{1,5-a}pyrimidine derivative and anti-inflammatory containing the same
FR2676734B1 (fr) 1991-05-23 1995-05-19 Roussel Uclaf Nouveaux derives de la pyrimidine, leur procede de preparation, les nouveaux intermediaires obtenus, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant.
US5336677A (en) 1991-10-24 1994-08-09 American Home Products Corporation Substituted aminopyrimidines as antihypertensives
JP3811196B2 (ja) * 1993-08-26 2006-08-16 武田薬品工業株式会社 エンドセリン拮抗剤、チエノピリミジン誘導体およびその製造法
DE4425143A1 (de) 1994-07-15 1996-01-18 Basf Ag Substituierte Pyrimidinverbindungen und deren Verwendung
IL117659A (en) 1995-04-13 2000-12-06 Dainippon Pharmaceutical Co Substituted 2-phenyl pyrimidino amino acetamide derivative process for preparing the same and a pharmaceutical composition containing same
US5843951A (en) 1995-09-28 1998-12-01 Otsuka Pharmaceutical Factory Inc. Analgesic composition of pyrazolo(1,5-A) pyrimidines
DE19600934A1 (de) 1996-01-12 1997-07-17 Basf Ag Substituierte Aza- und Diazacycloheptan- und Cyclooctanverbindungen und deren Verwendung
ID18046A (id) 1996-08-20 1998-02-19 Takeda Chemical Industries Ltd Senyawa siklik campuran, pembuatan dan penngunaannya.
US6432947B1 (en) 1997-02-19 2002-08-13 Berlex Laboratories, Inc. N-heterocyclic derivatives as NOS inhibitors
IN188411B (fr) 1997-03-27 2002-09-21 Yuhan Corp
US6194410B1 (en) 1998-03-11 2001-02-27 Hoffman-La Roche Inc. Pyrazolopyrimidine and pyrazolines and process for preparation thereof
SE9900211D0 (sv) 1999-01-25 1999-01-25 Pharmacia & Upjohn Ab New compounds
WO2001098301A1 (fr) 2000-06-20 2001-12-27 Japan Tobacco Inc. Composes de pyrazolopyridine et utilisation de ces derniers en tant que medicaments
JP3616628B2 (ja) 2001-03-01 2005-02-02 塩野義製薬株式会社 Ｈｉｖインテグラーゼ阻害活性を有する含窒素芳香族複素環化合物
CA2450934A1 (fr) 2001-06-19 2002-12-27 Marco Dodier Inhibiteurs pyrimidine de la phosphodiesterase (pde) 7
US7662826B2 (en) 2002-04-23 2010-02-16 Shionogi & Co., Ltd. Pyrazolo [1,5-a] pyrimidine derivative and nad (p) h oxidase inhibitor containing the same
US6759533B2 (en) 2002-06-28 2004-07-06 Boehringer Ingelheim Pharmaceuticals, Inc. Process and intermediates for making non-nucleoside HIV-1 reverse transcriptase inhibitors
SE0202838D0 (sv) 2002-09-24 2002-09-24 Astrazeneca Ab Chemical compounds
PA8586801A1 (es) 2002-10-31 2005-02-04 Pfizer Inhibidores de hiv-integrasa, composiciones farmaceuticas y metodos para su uso
US7550470B2 (en) 2002-12-11 2009-06-23 Merck & Co. Inc. Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors
US7176210B2 (en) 2003-02-10 2007-02-13 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
PT1471057E (pt) 2003-04-25 2006-05-31 Actimis Pharmaceuticals Inc Derivados de acido pirimidinilacetico uteis para o tratamento de doencas mediadas por crth2
US20050043327A1 (en) 2003-08-21 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
TW200523252A (en) 2003-10-31 2005-07-16 Takeda Pharmaceutical Pyridine compounds
DE10356579A1 (de) 2003-12-04 2005-07-07 Merck Patent Gmbh Aminderivate
US7875604B2 (en) * 2004-02-04 2011-01-25 University Of Virginia Patent Foundation Compounds that inhibit HIV particle formation
WO2006019832A1 (fr) * 2004-07-22 2006-02-23 Ptc Therapeutics, Inc. Thienopyridines utilisees pour traiter l'hepatite c
WO2006033796A1 (fr) 2004-09-17 2006-03-30 Wyeth Pyrazolo [1,5-a] pyrimidines substituees et leur procede de fabrication
JP2008524134A (ja) 2004-12-17 2008-07-10 エフ．ホフマン−ラ ロシュ アーゲー Ｇａｂａ−ｂアロステリックエンハンサーとしてのチエノ−ピリジン誘導体
JP2008530229A (ja) 2005-02-17 2008-08-07 ワイス シクロアルキル縮合インドール、ベンゾチオフェン、ベンゾフランおよびインデン誘導体
DE102005024245A1 (de) * 2005-05-27 2006-11-30 Merck Patent Gmbh Thienopyridine
WO2007062677A1 (fr) 2005-11-30 2007-06-07 7Tm Pharma A/S Acides thiazolyl et pyrimidinyl-acetiques et leurs utilisations comme ligands du recepteur crth2
EP2006288A4 (fr) 2006-01-23 2010-03-10 Kumiai Chemical Industry Co Derive d aminopyridine et agent de lutte contre une maladie de plantes destine a un usage agricole ou horticole
US7939545B2 (en) 2006-05-16 2011-05-10 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
KR20110089463A (ko) 2006-07-24 2011-08-08 한국화학연구원 신규 ｈｉｖ 역전사 효소 억제제
EP2132211A4 (fr) 2006-11-09 2011-12-07 Ardea Biosciences Inc Composés hétérocycliques bicycliques 4-cyanophénylamino-substitués utilisés comme inhibiteurs du vih
KR100811865B1 (ko) 2006-12-08 2008-03-10 주식회사 레고켐 바이오사이언스 인자 Ⅶａ 억제 활성을 갖는 피리미디논 또는 피리다지논유도체
ES2402322T3 (es) 2007-11-15 2013-04-30 Gilead Sciences, Inc. Inhibidores de la replicación del virus de la inmunodeficiencia humana
ATE541841T1 (de) 2007-11-15 2012-02-15 Boehringer Ingelheim Int Inhibitoren der replikation des human immunodeficiency virus
ES2463720T3 (es) 2007-11-16 2014-05-29 Gilead Sciences, Inc. Inhibidores de la replicación del virus de inmunodeficiencia humana
EA019259B1 (ru) 2007-11-16 2014-02-28 Джилид Сайенсиз, Инк. Ингибиторы репликации вируса иммунодефицита человека
DE102007061766A1 (de) 2007-12-20 2009-06-25 Bayer Healthcare Ag 4-(4-Cyano-2-thioaryl)-dihydropyrimidinone und ihre Verwendung
EP2393492A1 (fr) 2009-02-09 2011-12-14 Boehringer Ingelheim International GmbH Nouvelles compositions pharmaceutiques destinées au traitement de troubles respiratoires et gastro-intestinaux
GB0908394D0 (en) 2009-05-15 2009-06-24 Univ Leuven Kath Novel viral replication inhibitors
GB0913636D0 (en) 2009-08-05 2009-09-16 Univ Leuven Kath Novel viral replication inhibitors
SG181423A1 (en) 2009-12-23 2012-07-30 Univ Leuven Kath Novel antiviral compounds
WO2011151370A1 (fr) 2010-06-03 2011-12-08 Bayer Cropscience Ag N-[(het)arylalkyl)]pyrazole(thio)carboxamides et leurs analogues hétérosubstitués
EP2640729B1 (fr) 2010-11-15 2016-12-21 VIIV Healthcare UK Limited Inhibiteurs de la réplication du vih
KR20140003438A (ko) 2010-11-15 2014-01-09 카톨리에케 유니버시테이트 루벤 항바이러스성 축합 헤테로사이클릭 화합물
AU2011329233A1 (en) 2010-11-15 2013-05-23 Abbvie Deutschland Gmbh & Co Kg NAMPT and ROCK inhibitors

Also Published As

Publication number Publication date
UA104021C2 (ru) 2013-12-25
JP2016040299A (ja) 2016-03-24
AP2011005975A0 (en) 2011-12-31
CL2011002878A1 (es) 2012-06-22
US8785638B2 (en) 2014-07-22
EA201171376A1 (ru) 2012-05-30
ECSP11011456A (es) 2012-01-31
GEP20146115B (en) 2014-07-10
BRPI1010833A2 (pt) 2016-04-05
ZA201107618B (en) 2012-12-27
CN102459280B (zh) 2015-10-14
CA2759500A1 (fr) 2010-11-18
IL216357A0 (en) 2012-01-31
EP2430029A1 (fr) 2012-03-21
MX2011012146A (es) 2012-03-06
US9499563B2 (en) 2016-11-22
CU24117B1 (es) 2015-08-27
AU2010247366A1 (en) 2011-11-10
US20140296272A1 (en) 2014-10-02
KR20140127905A (ko) 2014-11-04
CN102459280A (zh) 2012-05-16
US20120059028A1 (en) 2012-03-08
CU20110208A7 (es) 2012-02-15
GB0908394D0 (en) 2009-06-24
TN2012000074A1 (fr) 2013-09-19
MY161085A (en) 2017-04-14
CR20110601A (es) 2012-04-30
CN105367583A (zh) 2016-03-02
NI201100194A (es) 2012-01-23
AP2939A (en) 2014-07-31
JP2012526778A (ja) 2012-11-01
WO2010130842A1 (fr) 2010-11-18
SG175255A1 (en) 2011-11-28
NZ596392A (en) 2014-06-27
DOP2011000343A (es) 2012-08-15
KR20120035162A (ko) 2012-04-13
PE20120779A1 (es) 2012-06-20
CO6460769A2 (es) 2012-06-15
EP2430029B1 (fr) 2018-01-10

Similar Documents

Publication Publication Date Title
MA33274B1 (fr) Dérivés de la thiéno [2, 3-b] pyridine servant d'inhibiteurs de réplication virale
US20240245637A1 (en) Mek-inhibitor for the treatment of viral and bacterial infections
MX2012007410A (es) Compuestos antivirales novedosos.
JOP20220267A1 (ar) مركبات أمينو ثيازول تحمل بدائل بصفتها مثبطات لـثنائي أسيل غليسرول كيناز زيتا لتنشيط المناعة
MA34400B1 (fr) Dérivés d'acide 2-quinolinyl-acétique en tant que composés antiviraux contre le vih
MA35114B1 (fr) 1,3-oxazines à titre d'inhibiteurs de bace1 et/ou de bace2
MX2013005478A (es) Compuestos heterociclicos condensados antivirales.
MA34013B1 (fr) Inhibiteurs du virus de l'hépatite c
MA35422B1 (fr) Imidazopyridazines amino-substituees
MA30406B1 (fr) Nouveaux composes
EP2509589B1 (fr) Compositions antivirales pharmaceutiques ou vétérinaires comprenant la midodrine ou la desglymidodrine
MA46342A (fr) Dérivés de chromane, d'isochromane et de dihydroisobenzofurane en tant que modulateurs allostériques négatifs de mglur2, compositions et leur utilisation
FR2952372B1 (fr) Nouveaux derives de mannopyranoside ayant une activite anticancereuse
EP4635494A3 (fr) Composés amido hétéroaromatiques
KR20160067225A (ko) 암 환자에서 근육 소모를 치료하는 선택적 안드로겐 수용체 조절물질 및 화학치료제
MA33979B1 (fr) Piperazines en tant qu'agents antipaludiques
WO2017174593A1 (fr) Nouvelles compositions antivirales pour le traitement de la grippe
KR101426996B1 (ko) 테트라케라 스캔덴스 에탄올 추출물을 유효성분으로 포함하는 항바이러스 조성물 및 이의 용도
JPWO2020004404A1 (ja) ＩＬ−１β阻害薬
JP2026506897A (ja) 無快感症の治療のための組成物および方法
HK40029715B (en) Novel mek-inhibitor for the treatment of viral and bacterial infections
HK40029715A (en) Novel mek-inhibitor for the treatment of viral and bacterial infections
MA38599A1 (fr) Nouveaux dérivés pyrazolopyrrolidine et leur utilisation dans le traitement de maladies
TH131128A (th) อนุพันธ์ไธอีโน [2,3-B] ไพริดีนเป็นตัวยับยั้งการเพิ่มจำนวนไวรัส (Thieno [2,3-B] Pyridine Derivatives as Viral Replication Inhibitors)